Skip to main content

A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients

Clinical Trial Grant
Duke Scholars

Administered By

Institutes and Centers

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

July 1, 2014

End Date

June 30, 2017
 

Administered By

Institutes and Centers

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

July 1, 2014

End Date

June 30, 2017